article thumbnail

U.S. Pharmaceutical company improved quality of overall documentation saving time and filing delays

Impact Pharmaceutical Services

Challenge Syner-G was contracted by a US Pharmaceutical Company to help improve the quality of submission documentation generated during the manufacture of a Drug Substance intended for Phase II trials. Results Syner-G reviewed each documentation and provided suggestions/comments/guidance to the CDMO to bridge the gaps observed.

article thumbnail

Leading patient adherence pharmaceutical companies

Pharmaceutical Technology

Discover the leading patient adherence pharmaceutical companies. Pharmaceutical Technology has listed the top patient adherence pharmaceutical companies based on our intel, insights and decades-long expertise in the sector. Patient adherence.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Process improvements and in-person monitoring help U.S. pharmaceutical company achieve on time for Phase III clinical trials

Impact Pharmaceutical Services

pharmaceutical company to oversee a 6 month, DS manufacturing as Person-In- Plant (PIP) and assist with preparation of associated submission documents related to Phase III clinical trial batches. pharmaceutical company achieve on time for Phase III clinical trials appeared first on SYNER-G.

article thumbnail

STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…

article thumbnail

NICE recommends first licenced treatment for AL amyloidosis

European Pharmaceutical Review

According to the Janssen Pharmaceutical Companies of Johnson & Johnson and NICE, DVCd is recommended for the rare bone marrow disorder, only if daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses.

article thumbnail

STAT+: Nostrum Laboratories and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates

STAT

A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising drug prices to controversial heights — agreed to pay up to $50 million to settle allegations of purposely underpaying Medicaid rebates. Department of Justice.

article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

Some pharmaceutical companies are increasing their R&D spending to increase product numbers. With major pharmaceutical companies implementing these approaches, this is a major contributing factor to rapid growth of this sector. Also noted in the report was the shift towards cloud-based systems.